Valuation: Clarity Pharmaceuticals Ltd

Market Cap 619M 424M 383M 353M 319M 604M 39.8B 4.24B 1.69B 21.32B 1.59B 1.56B 67.84B P/E 2027 *
-5.24x
P/E 2028 * -6.23x
Enterprise Value 555M 381M 343M 317M 286M 542M 35.69B 3.8B 1.51B 19.11B 1.43B 1.4B 60.83B EV / Sales 2027 *
-
EV / Sales 2028 * 16.1x
Free-Float
78.88%
Yield 2027 *
-
Yield 2028 * -
1 day+23.49%
1 week+28.12%
Current month+30.57%
1 month+6.77%
3 months-27.05%
6 months-28.07%
Current year-39.35%
1 week 1.46
Extreme 1.465
2.35
1 month 1.34
Extreme 1.34
2.35
Current year 1.34
Extreme 1.34
4.26
1 year 1.34
Extreme 1.34
4.4
3 years 1.12
Extreme 1.12
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 10/10/2024
Chief Executive Officer - 31/12/2009
Director of Finance/CFO - 03/04/2022
Director TitleAgeSince
Chairman - 31/10/2013
Director/Board Member - 30/09/2010
Director/Board Member 72 28/03/2016
Date Insider Type Main position Quantity % Market Cap. Importance
22/04/26 Sell

Chief Executive Officer

360,896 0.0969%
28/11/25 Free

Chief Operating Officer

199,909 0.0537%
28/11/25 Free

Chief Operating Officer

287,530 0.0773%
Change 5-day change 1-year change 3-year change Capi.($)
+23.49%+28.12%-53.30%+79.04% 424M
-1.06%-0.07%+60.76%+68.61% 67.53B
+1.10%+8.48%+13.73%+92.31% 60.74B
+0.03%-1.46%+19.47%+97.44% 55.66B
-0.95%+11.17%+22.21%+110.93% 47.97B
-0.23%+4.07%+25.63%+40.08% 45.24B
-6.40%-9.51%+181.99%+816.79% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-1.99%-4.21%+77.16%+54.21% 33.45B
+1.05%+9.77%-37.66%+408.42% 26.49B
Average +2.41%+4.34%+33.58%+181.88% 41B
Weighted average by Cap. +0.02%+1.67%+43.28%+167.96%

Financials

2027 *2028 *
Net sales - 33.03M 22.64M 20.4M 18.85M 17.04M 32.24M 2.12B 226M 90.04M 1.14B 84.95M 83.15M 3.62B
Net income -121M -82.71M -74.55M -68.87M -62.26M -118M -7.76B -825M -329M -4.15B -310M -304M -13.22B -101M -69.26M -62.43M -57.67M -52.14M -98.64M -6.5B -691M -275M -3.48B -260M -254M -11.07B
Net Debt -64M -43.86M -39.53M -36.52M -33.01M -62.46M -4.11B -438M -174M -2.2B -165M -161M -7.01B -87M -59.62M -53.73M -49.64M -44.88M -84.9M -5.59B -595M -237M -2.99B -224M -219M -9.53B
Projected Income Statement - Annual - Clarity Pharmaceuticals Ltd
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
100
Date Price Change Volume
12/11/26 A$2.050 +23.49% 11,203,152
10/11/26 A$1.660 +5.73% 2,075,702
09/11/26 A$1.570 +5.02% 2,244,194
06/11/26 A$1.495 -6.56% 2,483,676
05/11/26 A$1.600 +15.94% 6,024,779
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Clarity Pharmaceuticals Ltd
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.660AUD
Average target price
7.195AUD
Spread / Average Target
+333.43%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Clarity Pharmaceuticals Ltd